September 7, 2020
Akebia Therapeutics’ oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat, which is under codevelopment with Otsuka Pharmaceutical outside Japan, hit its primary and secondary efficacy endpoints in its two multinational PIII studies in adult patients on dialysis with anemia due...read more